ReShape Lifesciences Announces $750,000 Registered Direct Offering
08 nov. 2022 09h28 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
07 nov. 2022 13h22 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that...
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
03 nov. 2022 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the...
ReShape Lifesciences to Present at the Q4 Investor Summit
02 nov. 2022 09h11 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul...
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
31 oct. 2022 08h30 HE
|
ReShape Lifesciences Inc
Lap-Band® is the Only FDA Approved Device Indicated for Weight Reduction in Patients With a Body Mass Index (BMI) of at Least 40 kg/m2 or a BMI of at least 30 kg/m2 With One or More Obesity-Related...
ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
25 oct. 2022 08h30 HE
|
ReShape Lifesciences Inc
Data Shows ReShape’s DBSN™ System has Promise as a Novel, Adjustable and Localized Approach to Treat Type 2 Diabetes SAN CLEMENTE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™...
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
20 oct. 2022 08h30 HE
|
ReShape Lifesciences Inc
Active ASMBS Members, Comprised of Lap-Band® Clinical Experts, Participated in a Consensus Process to Yield Recommendations for Optimal Aftercare ASMBS Reasserts Endorsement of the...
ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
22 sept. 2022 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference
14 sept. 2022 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul...
ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations
23 août 2022 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...